breast cancer and glp-1 Could drugs help prevent cancer? New study points to a possible link GLP-1s: Weight Loss and Survival

NuRev Peptides is committed to quality and research integrity

Hoeffer and Klann, 2010

In the Phase 1 b trial of diabetic subjects, LY3298176 doses of 10 mg and 15 mg significantly reduced fasting serum glucose compared to placebo (least square mean [LSM] difference [95% CI]: -49.12 mg/dL [-78.14, -20.12] and -43.15 mg/dL [-73.06, -13.21], respectively)

It is important to note that no GLP-1 transdermal patches are currently licensed or approved for use in the UK

Some recent studies suggest GLP-1s are not cost-effective at their current prices, and increasing coverage could significantly raise overall spending, highlighting the challenge of balancing costs and benefits